Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Page 6 of 6
Feb 25, 2026This collaboration between Mayo Clinic and Merck represents a critical advancement in applying artificial intelligence to healthcare data, with an ambitious goal to improve the accuracy and utility of prognostic models. Leveraging patient data for AI training promises to facilitate earlier diagnosis and personalized treatment interventions across a spectrum of diseases.
Feb 14, 2026The infusion of $40 million funding into Anterior marks a significant advancement in leveraging artificial intelligence to transform administrative processes in healthcare. By enabling near-instantaneous care approvals, this technology promises to alleviate clinician burdens and optimize payer operations.
Feb 11, 2026While AI has been heralded for its potential in accelerating drug discovery, its immediate financial impact on major pharma firms is primarily driven by operational efficiencies and other innovative applications. Companies like Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb, and AstraZeneca exemplify this broader utilization of AI, reshaping the business of pharma.
Feb 4, 2026Epic's AI Charting technology leverages advanced AI methodologies to automate and enhance electronic health record documentation. This development could alter the landscape of ambient scribe services and redefine clinician workflows.
Feb 4, 2026As artificial intelligence technology continues to permeate healthcare, Alaffia Health is positioning itself to address the increasing need for efficiency among payers. By leveraging clinically informed AI to streamline administrative operations and reduce waste within healthcare claims, the company recently secured $55 million in investment to accelerate its platform's development and adoption. This funding milestone highlights the growing recognition of AI's role beyond providers and into payer organizations that face pressures to modernize systems and improve operational outcomes.
Jan 23, 2026The healthcare AI sector is poised for significant expansion in 2026, with transformative impacts expected across clinical applications, value-based care models, and data infrastructure. Bessemer’s insights underscore a surge in AI-driven innovation that could reshape patient care and health system efficiencies.
Jan 22, 2026Menopause and perimenopause have historically been areas of healthcare with limited personalized treatment options. The NIH-backed Amissa startup aims to change that narrative by leveraging artificial intelligence to aggregate and analyze data, providing improved care strategies for women undergoing these life stages. This detailed exploration delves into the technology behind Amissa's platform and its potential impact on women's health.
Jan 13, 2026At JPM 2026, Nvidia unveiled significant partnerships with leading pharma and life sciences companies including Eli Lilly and Thermo Fisher, illustrating its ambition to become a critical technology provider underpinning AI innovation in drug discovery and research laboratories worldwide.
Jan 12, 2026Both Anthropic and OpenAI are expanding their large language models into the healthcare sector, employing different strategies to integrate AI tools that address a variety of healthcare needs. Understanding their platforms’ design and targeted users offers insights into the evolving role of AI in medicine.
Jan 11, 2026The healthcare AI landscape has witnessed rapid innovation, with personalized health information tools becoming increasingly vital. Microsoft's initial foray with an AI product integrating deeply in health records has not seen recent developments, raising questions about strategic execution in this competitive domain.
Jan 8, 2026The new offering represents a significant development in AI-driven healthcare interactions, reflecting regulatory shifts as the FDA pursues a deregulatory stance on AI and digital health tools.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.